Stratos Wealth Partners LTD. Sells 90,000 Shares of Zevra Therapeutics, Inc. $ZVRA

Stratos Wealth Partners LTD. cut its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 29.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 220,000 shares of the company's stock after selling 90,000 shares during the period. Stratos Wealth Partners LTD. owned 0.40% of Zevra Therapeutics worth $1,938,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Rhumbline Advisers boosted its stake in shares of Zevra Therapeutics by 9.6% during the first quarter. Rhumbline Advisers now owns 74,585 shares of the company's stock valued at $559,000 after purchasing an additional 6,532 shares in the last quarter. Strs Ohio bought a new position in shares of Zevra Therapeutics during the first quarter valued at approximately $125,000. Woodline Partners LP boosted its stake in shares of Zevra Therapeutics by 11.5% during the first quarter. Woodline Partners LP now owns 4,615,625 shares of the company's stock valued at $34,571,000 after purchasing an additional 476,032 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after purchasing an additional 1,812 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. boosted its stake in shares of Zevra Therapeutics by 6.9% during the first quarter. Retirement Planning Co of New England Inc. now owns 550,180 shares of the company's stock valued at $4,121,000 after purchasing an additional 35,348 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Trading Up 3.1%

NASDAQ ZVRA opened at $11.15 on Tuesday. The company has a fifty day simple moving average of $9.33 and a two-hundred day simple moving average of $9.24. The stock has a market cap of $625.85 million, a P/E ratio of -53.10 and a beta of 1.49. Zevra Therapeutics, Inc. has a 12-month low of $6.19 and a 12-month high of $13.16. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($1.49). The company had revenue of $25.88 million during the quarter, compared to analysts' expectations of $22.49 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. On average, analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 19,500 shares of the firm's stock in a transaction on Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the transaction, the chief executive officer owned 222,016 shares of the company's stock, valued at approximately $2,402,213.12. This trade represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director John B. Bode purchased 5,000 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was bought at an average cost of $9.16 per share, with a total value of $45,800.00. Following the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $412,200. The trade was a 12.50% increase in their position. The disclosure for this purchase can be found here. Company insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Zevra Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday. JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating for the company in a research note on Wednesday, August 13th. HC Wainwright initiated coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 target price for the company. Weiss Ratings restated a "sell (d+)" rating on shares of Zevra Therapeutics in a research note on Tuesday, October 14th. Finally, Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.00.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.